Harbin Pharmaceutical Group Co., Ltd.

600664

CNE0000009T3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.01 ^CNY	+6.36%		+7.89%	-10.15%

Apr. 25	Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan	MT

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan	Apr. 11	MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Roxatidine Hydrochloride for Injection of Harbin Pharma's Subsidiary Passes Drug Regulator's Evaluation	Feb. 08	MT
Harbin Pharmaceutical Group's Cefotiam Hydrochloride Selected for China's Centralized Procurement Bid	Nov. 08	MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) added to S&P Global BMI Index	23-09-18	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-12	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-08	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-15	CI
Jian´anxi Food Technology Co., Ltd announced that it expects to receive $20 million in funding from Harbin Pharmaceutical Group Co., Ltd.	21-06-07	CI
Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product	21-05-17	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-02	CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI
News Highlights : Top Company News of the Day	20-09-18	DJ
News Highlights : Top Company News of the Day	20-09-17	DJ
News Highlights : Top Company News of the Day	20-09-17	DJ
News Highlights : Top Company News of the Day	20-09-17	DJ

Chart Harbin Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Harbin Pharmaceutical Group Co., Ltd.

More charts

Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Companyâs main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN PHARMACEUTICAL GROUP CO., LTD.	-10.15%	1.05B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B